{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:18:00Z","timestamp":1791271080830,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"2b","license":[{"start":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T00:00:00Z","timestamp":1340755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Experimental urethral obstruction in rats alters micturition patterns with non\u2010voiding activity (NVA) during filling cystometry, showing similarity to that observed in human detrusor overactivity. Several drug classes with therapeutic potential in overactive bladder in humans have been tested in this model in rats, rabbits or guinea pigs, but no detailed analysis of drug effects on cystometric patterns has been published.<\/jats:p>\n                    <jats:p>\n                      The present study uses a rat model of overactivity with partial bladder outflow obstruction (BOO) in combination with the procedures to analyse NVA to study the effects of the anticholinergic drug tolterodine and the novel \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      \u2010adrenoceptor agonist mirabegron. The current data for the first time show that NVA in rats with BOO is sensitive to both the muscarinergic antagonist tolterodine and the \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      \u2010adrenoceptor agonist mirabegron, but with clear differences between the two drugs: during progression of bladder filling, tolterodine affected both the amplitude and frequency of NVA whereas mirabegron affected primarily the frequency. In addition, tolterodine dose\u2010dependently reduced voiding contractions, while mirabegron did not. A model is proposed to account for these observations where both agents act on a \u2018pacemaker\u2010like\u2019 mechanism which is sensitive to cholinergic excitatory and beta\u2010adrenergic inhibitory inputs. Such concepts could provide insights into the nature of overactive bladder and the site of action of key therapeutic drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>\n                            To investigate the hypothesis that tolterodine and the \u03b2\n                            <jats:sub>3<\/jats:sub>\n                            \u2010adrenoceptor agonist mirabegron exert their actions on the motor component of the motor\/sensory system in the bladder wall: non\u2010voiding activity (NVA).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>The present study used standard cystometric techniques and a conscious rat model of partial bladder outflow obstruction (BOO). A single dose of either tolterodine (0.01, 0.1 0.3 or 1.0 mg\/kg) or mirabegron (0.03, 0.1, 0.3, 1.0 or 3.0 mg\/kg) was given i.v. to each animal.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>In the dose ranges used, tolterodine reduced the voiding contraction amplitude, whereas mirabegron did not.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Non\u2010voiding activity consisted of small (&lt;0.6 mmHg) and large (&gt;0.6 mmHg) transients.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>As a fill progressed, both tolterodine and mirabegron reduced the cumulative activity of the large non\u2010voiding contractions, but had little effect on the small transients.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Tolterodine affected both the amplitude and frequency of NVA, whereas mirabegron affected primarily the frequency.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>\n                            Non\u2010voiding activity is sensitive to muscarinergic antagonists and \u03b2\n                            <jats:sub>3<\/jats:sub>\n                            \u2010adrenoceptor agonists, but there are clear differences between the two drugs.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>A model is proposed to account for these observations where both agents act on a \u2018pacemaker\u2010like\u2019 mechanism with cholinergic excitatory and adrenergic inhibitory inputs.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Such concepts may provide insights into the nature of overactive bladder and the site of action of key therapeutic drugs.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11240.x","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T12:35:27Z","timestamp":1340800527000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Modulation of non\u2010voiding activity by the muscarinergic antagonist tolterodine and the \u03b2\n                    <sub>3<\/sub>\n                    \u2010adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction"],"prefix":"10.1111","volume":"110","author":[{"given":"James I.","family":"Gillespie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Palea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Guilloteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Guerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lluel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"Korstanje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,27]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10099"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)44485-5"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62305-X"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07307.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0022-3565(24)38287-4","article-title":"Comparison of the potassium channel openers, WAY\u2010133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat","volume":"289","author":"Wojdan A","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1991.tb15251.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00257.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.10.023"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(10)60758-0"},{"key":"e_1_2_7_12_2","unstructured":"NittiV HerschornS AuerbachSet\u2003al.The efficacy and safety of mirabegron in patients with overactive bladder syndrome \u2013 results from a North\u2010American Phase III trial. Presented at the 26th Annual Congress of the European Association of Urology Vienna Austria 18\u201322 March 2011"},{"key":"e_1_2_7_13_2","unstructured":"KhullarV CambroneroJ StrobergPet\u2003al.The efficacy and tolerability of mirabegron in patients with overactive bladder \u2013 results from a European\u2010Australian Phase III trial. Presented at the 26th Annual Congress of the European Association of Urology Vienna Austria 18\u201322 March 2011"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20841"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-201X.1998.00406.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0022-3565(24)38094-2","article-title":"Evidence for \u03b23\u2010adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods","volume":"288","author":"Takeda M","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200101000-00071"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61994-3"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3565(24)39317-6","article-title":"Role of the \u03b23\u2010adrenoceptor in urine storage in the rat: comparison between the selective \u03b23\u2010adrenoceptor agonist, CL316,243, and various smooth muscle relaxants","volume":"293","author":"Takeda H","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65936-8"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10034"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.115840"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06137.x"},{"key":"e_1_2_7_24_2","volume-title":"Elements of Human Physiology","author":"Starling EH","year":"1905"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1955.sp005327"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0301-0082(95)80012-W"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04667.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08377.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1996.08981.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2401"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000069722.35137.e0"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)34925-X"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1965.tb04287.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.1992.68.5.1842"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04626.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07129.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.02.057"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20826"},{"key":"e_1_2_7_39_2","first-page":"21290228","article-title":"Urothelial signalling","volume":"207","author":"Birder LA","year":"2011","journal-title":"Handb Exp Pharmacol"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11240.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11240.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:04:02Z","timestamp":1761746642000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11240.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,27]]},"references-count":38,"journal-issue":{"issue":"2b","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11240.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11240.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,27]]},"assertion":[{"value":"2012-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}